ライフサイエンスコーパス: visceral adipose tissue

1 s (body mass index, waist circumference, and visceral adipose tissue).

2 IL-1beta levels and decreased ILC markers in visceral adipose tissue.

3 sulin sensitivity and collagen deposition in visceral adipose tissue.

4 city between human DM and non-diabetic (NDM) visceral adipose tissue.

5 = 0.02) was attenuated after controlling for visceral adipose tissue.

6 d arteries, subcutaneous adipose tissue, and visceral adipose tissue.

7 lipoprotein lipase and up-regulated Socs3 in visceral adipose tissue.

8 storage, perhaps by suppressing lipolysis in visceral adipose tissue.

9 changes in body weight, body composition, or visceral adipose tissue.

10 nd were highly correlated with each other in visceral adipose tissue.

11 s were observed in human subcutaneous versus visceral adipose tissue.

12 pically seen in diabetes, and hypertrophy of visceral adipose tissue.

13 the abdominal aorta and in subcutaneous and visceral adipose tissue.

14 plant-based diets was associated with lower visceral adipose tissue.

15 R, 2.3; 95% CI, 1.1-4.9) after adjusting for visceral adipose tissue.

16 cyte compartment and fewer M1 macrophages in visceral adipose tissue.

17 y among adolescents even after adjusting for visceral adipose tissue.

18 nd constitutively at mucosal surfaces and in visceral adipose tissue.

19 d secretory phenotype (SASP) specifically in visceral adipose tissue.

20 ated genes as compared with subcutaneous and visceral adipose tissues.

21 riectomy and exhibited increased estrogen in visceral adipose tissues.

22 5, after adjustment for changes in weight or visceral adipose tissue].

23 plant-based diet index, percentage change in visceral adipose tissue: -4.9%, 95% CI: -8.6%, -2.0%).

24 Visceral adipose tissue, a marker of central adiposity,

25 t are at high risk if they have an excess of visceral adipose tissue-a condition often accompanied by

26 s we measured are not a predominant cause of visceral adipose tissue accumulation.

27 udies over the past 30 years have shown that visceral adipose tissue, accurately measured by CT or MR

28 d body composition [total, subcutaneous, and visceral adipose tissue; adipose tissue-free mass (ATFM)

29 ammatory pathways were measured in liver and visceral adipose tissue after 10 weeks.

30 Similarly, no difference was found in visceral adipose tissue and abdominal subcutaneous fat a

31 as a target of nuclear receptor PPARgamma in visceral adipose tissue and as a critical factor in adip

32 appears to be preferentially produced by the visceral adipose tissue and has insulin mimetic actions.

33 in adult locomotor activity, alterations in visceral adipose tissue and hepatic development, and per

34 Weight loss dose-dependently decreases visceral adipose tissue and liver fat content, and it im

35 subfraction particle size, and reduction in visceral adipose tissue and liver fat, independent of we

36 Primary end points were changes in visceral adipose tissue and liver fat.

37 Hence, excessive amounts of visceral adipose tissue and of ectopic fat largely defin

38 dysglycemia and dyslipidemia independent of visceral adipose tissue and other obesity measures.

39 During obesity, macrophages infiltrate the visceral adipose tissue and promote inflammation that co

40 Visceral adipose tissue and subcutaneous abdominal adipo

41 We measured the visceral adipose tissue and subcutaneous adipose tissue

42 cord and used by two operators to quantitate visceral adipose tissue and subcutaneous adipose tissue

43 Visceral adipose tissue and subcutaneous adipose tissue

44 roduction of antiinflammatory eicosanoids in visceral adipose tissue and subcutaneous adipose tissue

45 Analysis of paired mesenteric visceral adipose tissue and tumor samples from the study

46 M1/M2 macrophages within the peritoneal and visceral adipose tissues and higher percentages of TNF(+

47 Incubation of inflamed Ob visceral adipose tissues and human macrophages with RvD1

48 ased Wnt expression in both subcutaneous and visceral adipose tissues and impaired adipogenic differe

49 ndependent of coronary artery calcium score, visceral adipose tissue, and 10-year global cardiovascul

50 e cross-sectional abdominal subcutaneous and visceral adipose tissue, and computed tomography (CT) of

51 tion of limb and trunk fat, subcutaneous and visceral adipose tissue, and increased total cholesterol

52 in impaired accumulation of T(reg) cells in visceral adipose tissue, and is associated with enlarged

53 he change in total abdominal adipose tissue, visceral adipose tissue, and SAT at 24 mo (P = 0.01, 0.0

54 erence (WC), total abdominal adipose tissue, visceral adipose tissue, and subcutaneous adipose tissue

55 and HDL were strongest for WC, MRI-measured visceral adipose tissue, and WHR; in all cases, differen

56 th morbid obesity, and subcutaneous, but not visceral, adipose tissue angiogenic capacity correlated

57 sponses and immunopathological phenotypes in visceral adipose tissue are drastically reduced in cavef

58 Body mass index, visceral adipose tissue area (cm(2)), lipids, leptin, fr

59 Visceral adipose tissue area (treatment effect [last-val

60 ) at the 25th, 50th, and 75th percentiles of visceral adipose tissue area, respectively (p = 0.001),

61 orts the notion that elevated CCL2 levels in visceral adipose tissue associated with Metabolic Syndro

62 hibited higher expression levels of IL-32 in visceral adipose tissue (AT) as well as in subcutaneous

63 iated with chronic low-grade inflammation of visceral adipose tissue (AT) characterized by an increas

64 sonance imaging to quantify subcutaneous and visceral adipose tissue (AT).

65 ic-euglycemic clamp with skeletal muscle and visceral adipose tissue biopsies at baseline and at 30 a

66 propria (LP) of the small intestine, brain, visceral adipose tissue, bone marrow (BM), spleen, and t

67 Among the subset of obese participants, visceral adipose tissue, but not abdominal subcutaneous

68 ured by dual-energy X-ray absorptiometry and visceral adipose tissue by computerized tomography.

69 s, unlike diverticulitis, PNLIP leaking into visceral adipose tissue can cause excessive visceral adi

70 y molecules from other tissues, particularly visceral adipose tissue, can also induce muscle inflamma

71 sue samples (subcutaneous adipose tissue and visceral adipose tissue), collected during surgery after

72 y biomarker expression in three key tissues: visceral adipose tissue, colon (local inflammatory site)

73 elements in the portal vasculature, and even visceral adipose tissue communicate with the controllers

74 data set, for the subcutaneous, muscle, and visceral adipose tissue compartments, respectively.

75 d frequency of regulatory T cells (Tregs) in visceral adipose tissue contribute to the propagation of

76 Accumulation of visceral adipose tissue correlates with elevated inflamm

77 An excess of visceral adipose tissue could be involved as a modulator

78 Vaspin (visceral adipose tissue-derived serine protease inhibito

79 Visceral adipose tissue-derived serpin (vaspin), serpin

80 ance of normal weight for approximately 1 y, visceral adipose tissue distribution in AN patients was

81 elial interactions and macrophage content of visceral adipose tissue due to Psgl-1 deficiency was als

82 d to enhanced insulin signaling in liver and visceral adipose tissue (epididymal white adipose tissue

83 er additional adjustment for body weight and visceral adipose tissue, except for pericardial fat and

84 Visceral adipose tissue exhibited significantly blunted

85 creased the expression of lipogenic genes in visceral adipose tissue explants and intracellular calci

86 Finally, visceral adipose tissue explants were cultured with reco

87 creased SPARC production dose dependently in visceral adipose tissue explants, while glucose decrease

88 resulted in hyperresistinemia and increased visceral adipose tissue expression of suppressor of cyto

89 mote the resolution of inflammation in human visceral adipose tissue from obese (Ob) patients.

90 A proteomic analysis of visceral adipose tissue from patients with obesity and p

91 The proteomic analysis of the visceral adipose tissue from patients with obesity show

92 Visceral adipose tissue GPR55 correlated positively with

93 Lower liver fat content and visceral adipose tissue, greater insulin sensitivity and

94 Whether visceral adipose tissue has a uniquely powerful associat

95 ty and subcutaneous body fat, differences in visceral adipose tissue have not been evaluated.

96 alcohol, food insecurity, physical activity, visceral adipose tissue, HIV and menopausal status were

97 nt for more than 20% of stromal cells within visceral adipose tissues; however, their functions in th

98 ssion of E2F1 in adipocyte fraction of human visceral adipose tissue (hVAT) associates with a poor ca

99 Pancreatic lipase injected into mouse visceral adipose tissue hydrolyzed adipose triglyceride

100 We biopsied paired subcutaneous and visceral adipose tissue in 40 obese subjects (body mass

101 rotein A3 (Foxa3) regulates the expansion of visceral adipose tissue in high-fat diet regimens; howev

102 ssed in brown adipose tissue in rodents, and visceral adipose tissue in humans.

103 tion in body weight, intrahepatic lipid, and visceral adipose tissue in patients who received liraglu

104 ne variant have an impaired capacity to lose visceral adipose tissue in response to prolonged caloric

105 There was significantly more visceral adipose tissue in the subgroup of HIV-infected

106 study was performed to elucidate the role of visceral adipose tissue in whole-body glucose homeostasi

107 ake is reduced in subcutaneous abdominal and visceral adipose tissues in IGT(+) directly associated w

108 cient mice have multiple histopathologies in visceral adipose tissue, including increased adipocyte d

109 measure skeletal muscle and subcutaneous and visceral adipose tissue indexes.

110 c measurements, greater skeletal muscle, and visceral adipose tissue indices were independently assoc

111 AHR, lung and visceral adipose tissue inflammation, humoral response,

112 Visceral adipose tissue is a major site for expression o

113 Chronic inflammation in visceral adipose tissue is considered a key element for

114 tion of adipose tissue into subcutaneous and visceral adipose tissue is required.

115 visceral adipose tissue can cause excessive visceral adipose tissue lipolysis independently of adipo

116 It has been hypothesized that visceral adipose tissue lipolysis releases excess FFAs i

117 We conclude that the contribution of visceral adipose tissue lipolysis to hepatic FFA deliver

118 adipocyte-specific ATGL knockouts, had lower visceral adipose tissue lipolysis, milder inflammation,

119 gher CRP, and higher fat in subcutaneous and visceral adipose tissue, liver, and pancreas for UFA and

120 effect of the Trp64Arg variant on total and visceral adipose tissue loss, insulin sensitivity, and c

121 DPP-4i reduced visceral adipose tissue macrophage content (adipose tiss

122 minal subcutaneous adipose tissue, increased visceral adipose tissue, marked IR, dyslipidemia, and fa

123 ific CD1d deletion decreased the size of the visceral adipose tissue mass and enhanced insulin sensit

124 Iron supplemented mice had lower visceral adipose tissue mass estimated by epididymal fat

125 though whole-body fat mass was not affected, visceral adipose tissue mass tended to decrease after th

126 tage of fat mass, total adipose tissue mass, visceral adipose tissue mass, and superficial adipose ti

127 s have been specifically linked to increased visceral adipose tissue mass.

128 etion of a host of inflammatory factors from visceral adipose tissue may contribute to the increased

129 d at overcoming glucocorticoid resistance in visceral adipose tissue may improve remodeling and help

130 sment of body fat distribution, particularly visceral adipose tissue, may be important for accurate r

131 Tesamorelin significantly reduced visceral adipose tissue (mean change, -34 cm2 [95% CI, -

132 istance and hypertriglyceridemia and affects visceral adipose tissue metabolism by a mechanism involv

133 ndothelium interaction by fatty acids in the visceral adipose tissue microcirculation.

134 Visceral adipose tissue MMP14 expression correlated stro

135 odel of diet-induced obesity, Tregs from the visceral adipose tissue of hyperinsulinemic, obese mice

136 e phospho-Akt/Akt ratio, was detected in the visceral adipose tissue of iron overloaded mice, and gen

137 n inflammatory (type 1) CD11c(+) ATMs in the visceral adipose tissue of Mgl1(-/-) mice.

138 s (ILC2s) was also observed in the lungs and visceral adipose tissue of Nfil3-deficient mice, reveali

139 ols, GS-HNE and GS-DHN were more abundant in visceral adipose tissue of ob/ob mice and diet-induced o

140 Similarly, in whole animals, visceral adipose tissue of STAMP2(-/-) mice exhibits ove

141 vanced ovarian cancer usually spreads to the visceral adipose tissue of the omentum.

142 bers were decreased in both subcutaneous and visceral adipose tissue of TRPC1 KO mice fed a HF diet a

143 risk, especially in women, correlating with visceral adipose tissue (P < 0.0001) and triglycerides (

144 io (P < 0.006), total trunk fat (P < 0.003), visceral adipose tissue (P < 0.006), and intramuscular a

145 hma had increased macrophage infiltration of visceral adipose tissue (P < 0.01), with increased expre

146 ngest correlate of serum triacylglycerol was visceral adipose tissue (P = 0.002 for both women and me

147 2 years) underwent assessment of fat depots (visceral adipose tissue, pericardial adipose tissue, and

148 eous adipose tissue (ingSAT) and perigonadal visceral adipose tissue (pgVAT) is promoted by the deple

149 lectively, these studies illuminate adaptive visceral adipose tissue plasticity in obese mice in resp

150 Visceral adipose tissue plays a critical role in numerou

151 Pericardial fat, intrathoracic fat, and visceral adipose tissue quantified from multidetector co

152 muscle (r = 0.825; P = .003), and abdominal visceral adipose tissue (r = 0.820; P = .004).

153 intrathoracic fat (r=0.17 to 0.31, P<0.001), visceral adipose tissue (r=0.19 to 0.36, P<0.001), body

154 intrathoracic fat (r=0.25 to 0.37, P<0.001), visceral adipose tissue (r=0.24 to 0.45, P<0.001), body

155 er insulin levels and higher subcutaneous-to-visceral adipose tissue ratio and may protect from disea

156 ciation of the healthy plant-based diet with visceral adipose tissue remained statistically significa

157 sed activation of HIF-1alpha in ATM of obese visceral adipose tissue resulted in induction of IL-1bet

158 The omentum is a visceral adipose tissue rich in fat-associated lymphoid

159 In this review, we discuss the roles of visceral adipose tissue's salient leukocyte lineages in

160 Abdominal subcutaneous and visceral adipose tissue (SAT and VAT) were reduced (494

161 e determined in biopsies of subcutaneous and visceral adipose tissue (SCAT and VAT, respectively) fro

162 loaded mice, and gene expression analysis of visceral adipose tissue showed that an iron-enriched die

163 d tissue-Treg populations-those operating in visceral adipose tissue, skeletal muscle, and the coloni

164 ale sex, alanine aminotransferase levels and visceral adipose tissue/subcutaneous adipocyte size rati

165 er 90-day mortality than patients with lower visceral adipose tissue/subcutaneous adipose tissue (log

166 eous adipose tissue than in those with lower visceral adipose tissue/subcutaneous adipose tissue (p =

167 Sepsis patients with higher visceral adipose tissue/subcutaneous adipose tissue had

168 apy, and ICU stay in patients in the highest visceral adipose tissue/subcutaneous adipose tissue quar

169 t covariates using Cox regression, increased visceral adipose tissue/subcutaneous adipose tissue quar

170 os of 2.01 (95% CI, 1.01-3.99) for the third visceral adipose tissue/subcutaneous adipose tissue quar

171 and 2.32 (95% CI, 1.15-4.69) for the highest visceral adipose tissue/subcutaneous adipose tissue quar

172 e levels was greater in patients with higher visceral adipose tissue/subcutaneous adipose tissue than

173 Visceral adipose tissue/subcutaneous adipose tissue was

174 Increased mortality for patients with higher visceral adipose tissue/subcutaneous adipose tissue was

175 and subcutaneous adipose tissue but greater visceral adipose tissue than HIV-infected patients witho

176 Pericardial fat is visceral adipose tissue that possesses inflammatory prop

177 rs that metastasize to a specific example of visceral adipose tissue, the omentum.

178 Addition of visceral adipose tissue to a multivariable model that in

179 est that TNMD acts as a protective factor in visceral adipose tissue to alleviate insulin resistance

180 between men and women in the contribution of visceral adipose tissue to hepatic FFA delivery, most st

181 eous adipose tissue areas and calculated the visceral adipose tissue-to-subcutaneous adipose tissue r

182 Visceral obesity, defined by a high visceral adipose tissue-to-subcutaneous adipose tissue r

183 ress type 2 cytokines, and share features of visceral adipose tissue Treg cells.

184 of fatty acids released during lipolysis of visceral adipose tissue triglycerides to portal and syst

185 1000 kcal) were associated with decreases in visceral adipose tissue (VAT) (r = -0.29, P = 0.02, and

186 PAI-1 was positively associated with visceral adipose tissue (VAT) (r = 0.49, P < 0.01), SAAT

187 maging and spectroscopy were used to measure visceral adipose tissue (VAT) and liver fat fraction (LF

188 zebrafish induced hyperplastic morphology in visceral adipose tissue (VAT) and reduced lipid storage.

189 The cellular composition of visceral adipose tissue (VAT) and release of cytokines b

190 Visceral adipose tissue (VAT) and subcutaneous adipose t

191 etic resonance spectroscopy and LV function, visceral adipose tissue (VAT) and subcutaneous adipose t

192 bolic and transcriptomic differences between visceral adipose tissue (VAT) and subcutaneous adipose t

193 Visceral adipose tissue (VAT) and subcutaneous adipose t

194 was to examine the differences in abdominal visceral adipose tissue (VAT) and subcutaneous adipose t

195 Visceral adipose tissue (VAT) and subcutaneous adipose t

196 The effect of visceral adipose tissue (VAT) and subcutaneous adipose t

197 ciation of habitual SSB intake and change in visceral adipose tissue (VAT) and subcutaneous adipose t

198 accumulation and activation of leukocytes in visceral adipose tissue (VAT) and ultimately other tissu

199 Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) are associated with advers

200 between HIV-related microbiota signature and visceral adipose tissue (VAT) area (P for interaction =

201 Abdominal subcutaneous (SAT) and visceral adipose tissue (VAT) areas and hepatic fat (%)

202 Dual-energy x-ray absorptiometry (DXA) for visceral adipose tissue (VAT) assessment is used as an a

203 ms to measure total adipose tissue (TAT) and visceral adipose tissue (VAT) at the umbilicus (L4 verte

204 ormone-releasing hormone analogue, decreases visceral adipose tissue (VAT) by 15%-20% over 6-12 month

205 Visceral adipose tissue (VAT) compartments may confer in

206 During obesity, the hypertrophy of visceral adipose tissue (VAT) contributes to muscle dysf

207 ite ample evidence to confirm that increased visceral adipose tissue (VAT) deposition occurs with obe

208 ominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) depth.

209 omography to evaluate subcutaneous (SAT) and visceral adipose tissue (VAT) distribution and had anthr

210 Visceral adipose tissue (VAT) has been identified as a h

211 Eosinophils in visceral adipose tissue (VAT) have been implicated in me

212 nts of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in children treated for ma

213 iver, subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT) in morbidly obese subjects

214 e juice (OJ) on weight loss and reduction of visceral adipose tissue (VAT) in overweight and obese ad

215 growth factor binding protein (IGFBP) 3, and visceral adipose tissue (VAT) in subjects with adenomato

216 ariate analysis, plasma adiponectin, AD, and visceral adipose tissue (VAT) independently predicted IH

217 tion of non-canonical WNT5A/PCP signaling to visceral adipose tissue (VAT) inflammation and associate

218 zed by T cell and macrophage infiltration of visceral adipose tissue (VAT) is a hallmark of obesity-a

219 Visceral adipose tissue (VAT) is a primary site for stor

220 In several white populations, visceral adipose tissue (VAT) is a risk factor for devel

221 Visceral adipose tissue (VAT) is an important risk facto

222 Visceral adipose tissue (VAT) is an important risk facto

223 It is well established that visceral adipose tissue (VAT) is associated with increas

224 In particular, visceral adipose tissue (VAT) is critical for the regula

225 In obese individuals, visceral adipose tissue (VAT) is the seat of chronic low

226 ntervention on food intake, body weight, and visceral adipose tissue (VAT) mass; plasma, lipids (chol

227 aluated by quantitative real-time PCR in the visceral adipose tissue (VAT) of 35 obese subjects under

228 d expression of some adipogenesis markers in visceral adipose tissue (VAT) of HFD-fed M-JAK2(-/-) mic

229 )CD4(+) regulatory T (Treg) cells resides in visceral adipose tissue (VAT) of lean mice, especially i

230 driving the adaptive Th17 response in human visceral adipose tissue (VAT) of metabolically unhealthy

231 r fitness, percentage of body fat (%BF), and visceral adipose tissue (VAT) of obese adolescents.

232 The degree of unsaturation was lower in visceral adipose tissue (VAT) phospholipids, indicating

233 grouped them by MRI-derived visceral fat to visceral adipose tissue (VAT) plus SAT (VAT/VAT+SAT) rat

234 Chronic inflammation in visceral adipose tissue (VAT) precipitates the developme

235 he inflammasome protein cryopyrin (NLRP3) in visceral adipose tissue (VAT) promotes release of the pr

236 Men are believed to have more visceral adipose tissue (VAT) than women have, but studi

237 ce triggers an adaptive tissue remodeling in visceral adipose tissue (VAT) that involves extracellula

238 f Foxp3+ regulatory T cells (TRs) resides in visceral adipose tissue (VAT) that regulates adipose inf

239 ombinant human growth hormone (rhGH) reduces visceral adipose tissue (VAT) volume in HIV-infected pat

240 Subcutaneous adipose tissue (SAT) volume, visceral adipose tissue (VAT) volume, and VAT/SAT ratio

241 uently chosen to approximate total abdominal visceral adipose tissue (VAT) volume, but growing eviden

242 82 had subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) volumes measured by multid

243 and MRI for abdominal subcutaneous (SAT) and visceral adipose tissue (VAT) volumes.

244 Visceral adipose tissue (VAT) was collected at d17.5 of

245 Visceral adipose tissue (VAT) was measured by computed t

246 abdominal obesity, especially enlargement of visceral adipose tissue (VAT), a tissue with important i

247 Liver fat, visceral adipose tissue (VAT), abdominal subcutaneous ad

248 ide murine Treg cell clone isolated from the visceral adipose tissue (VAT), and identified surrogate

249 les of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), and phenotypes and functi

250 nthropometry, body composition, hepatic fat, visceral adipose tissue (VAT), and pre- and postcold PDF

251 midthigh MRI slice to assess whole-body SM, visceral adipose tissue (VAT), and subcutaneous adipose

252 ominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), assessed by multidetector

253 ed with an influx of pathogenic T cells into visceral adipose tissue (VAT), but the mechanisms regula

254 have increased body weight, amount of total visceral adipose tissue (VAT), fasting blood glucose and

255 In visceral adipose tissue (VAT), HFD exposure determined a

256 IR subjects exhibited significantly greater visceral adipose tissue (VAT), intrahepatic lipid (IHL),

257 mmatory Index (E-DII score), total fat mass, visceral adipose tissue (VAT), or liver fat (percentage

258 Visceral adipose tissue (VAT), subcutaneous abdominal ad

259 mass index (BMI) and areas and densities of visceral adipose tissue (VAT), subcutaneous adipose tiss

260 l-body skeletal muscle (SM) and increases in visceral adipose tissue (VAT), subcutaneous adipose tiss

261 ) in T cells in skewing adaptive immunity in visceral adipose tissue (VAT), thereby contributing to d

262 Abdominal subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), thigh SAT, and thigh inte

263 Visceral adipose tissue (VAT), which is linked with the

264 formation, we used a novel ex vivo system of visceral adipose tissue (VAT)-condition medium-stimulate

265 3 (DR3), a member of the TNF superfamily, on visceral adipose tissue (VAT)-derived murine and periphe

266 e and inflammation thought to be caused by a visceral adipose tissue (VAT)-localized reduction in imm

267 l adipose tissue depots increased except for visceral adipose tissue (VAT).

268 ssion in DC/macrophage cell populations from visceral adipose tissue (VAT).

269 mice by activating its Y2 receptor (Y2R) in visceral adipose tissue (VAT).

270 depend on accompanying amounts of abdominal visceral adipose tissue (VAT).

271 ominal subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT).

272 n both subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT).

273 pressed in Treg cells, particularly those in visceral adipose tissue (VAT).

274 ibution, and the main specific end point was visceral adipose tissue (VAT).

275 e associated with higher levels of visceral [visceral adipose tissue (VAT)] and deep subcutaneous [de

276 leterious metabolic effects of visceral fat [visceral adipose tissue (VAT)] deposition were challenge

277 ls predominantly in visceral adipose depots [visceral adipose tissue (VAT)] rather than in subcutaneo

278 Foxp3(+) regulatory T (Treg) cells in visceral adipose tissue (VAT-Treg cells) are functionall

279 inal subcutaneous fat [SAT], adipose tissue, visceral adipose tissue [VAT], and muscle) from patients

280 at distribution (for example, a high vs. low visceral adipose tissue [VAT]/[VAT + subcutaneous adipos

281 A second paradox emerged from CT analyses of visceral adipose tissue, viewed as an unhealthy fat depo

282 n, male participants lost significantly more visceral adipose tissue volume (1.76 L vs 0.91 L; P < .0

283 4, p<0.0001), HOMA2-IR (r=0.74, p=0.01), and visceral adipose tissue volume (r=0.74, p=0.036).

284 s index (r=0.73, p<0.0001), subcutaneous and visceral adipose tissue volumes (r=0.94 and r=0.87, resp

285 significant differences in subcutaneous and visceral adipose tissue volumes and ratios.

286 However, loss of visceral adipose tissue was 43% lower in carriers of the

287 Visceral adipose tissue was also associated with lower c

288 For women, visceral adipose tissue was an independent predictor of

289 After multivariable adjustment, visceral adipose tissue was associated with cardiovascul

290 After multivariable adjustment, visceral adipose tissue was associated with concentric r

291 Visceral adipose tissue was not associated with adenoma

292 n 2 cm(3) biopsy samples of subcutaneous and visceral adipose tissue were obtained.

293 ractant protein-1, and macrophage content of visceral adipose tissue were reduced in Lepr(db/db),Psgl

294 atio was found in metabolically more harmful visceral adipose tissue when compared to subcutaneous ad

295 of tdTomato-C3aR in the brain, lung, LP, and visceral adipose tissue, whereas it was minor in the spl

296 eding reduces senescent phenotype markers in visceral adipose tissue while attenuating physical impai

297 The association of visceral adipose tissue with MI in women was independent

298 with normal insulin sensitivity and healthy visceral adipose tissue with normal adiponectin function

299 Given the unique association of visceral adipose tissue with obesity-related metabolic d

300 The omentum is a visceral adipose tissue with unique immune functions.